91ºÚÁÏÍø

Edward A Fon, MD, FRCP(C)

Edward A Fon, MD, FRCP(C)
Contact Information
Phone: 
514-398-5957
Fax number: 
514-398-5214
Email address: 
edward.fon [at] mcgill.ca
Hospital title: 
Director, The Neuro (Montreal Neurological Institute-Hospital), of the Faculty of Medicine and Health Sciences at 91ºÚÁÏÍø and 91ºÚÁÏÍø Health Centre-Santé Québec (MUHC-Santé Québec)
Chief of the Neuroscience Mission at MUHC-Santé Québec
Wilder Penfield Chair in Neuroscience and Professor of Neurology and Neurosurgery, 91ºÚÁÏÍø
Canada Research Chair (Tier 1) in Parkinson's Disease
Location: 
Movement Disorders Programme
Biography: 

An attending neurologist, professor and clinician-scientist listed among the top 1% most cited researchers in the world by Clarivate, Dr. Fon served as Scientific Director of The Neuro from 2015 to 2026, and Associate Chair, Neuroscience, Department of Neurology and Neurosurgery since 2016. He is also Director of the 91ºÚÁÏÍø Parkinson Program (a Parkinson's Foundation Centre of Excellence) and Co-Director of the Canadian Open Parkinson Network. Dr. Fon assumed his new functions as Director of The Neuro on June 1, 2026, succeeding Dr. Guy Rouleau.

Dr. Fon earned his M.D. from Université de Montréal in 1989, completed a neurology residency and a clinical and research fellowship in neurogenetics at 91ºÚÁÏÍø, and pursued postdoctoral training at the University of California, San Francisco, where his genetic studies advanced the understanding of dopamine transmission. He returned to The Neuro in 1999 as a faculty member.

Since then, his research has focused on the molecular mechanisms underlying the neurodegeneration in Parkinson's disease, with particular emphasis on α-synuclein, GBA1, LRRK2, Parkin, and PINK1—genes implicated in familial forms of the disease. Through the development of patient-derived induced pluripotent stem cell (iPSC) models, his work is paving the way for innovative therapeutic strategies by shedding light on the mechanisms of neurodegeneration.

A Fellow of the Royal College of Physicians of Canada and an elected member of the American Society for Clinical Investigation, Dr. Fon holds a Tier 1 Canada Research Chair in Parkinson's Disease and is supported by the CIHR, Brain Canada, Canada Foundation for Innovation, FRQS, and the Michael J. Fox Foundation.

Selected publications: 

Tang MY, Vranas M, Krahn A, Pundlik S, Trempe JF,ÌýFonÌýEA. Structure-guided mutagenesis reveals a hierarchical mechanism of Parkin activation.ÌýNat. Commun.Ìý2017; 8:14697. doi: 10.1038/ncomms14697

McLelland GL, Lee SA, McBride HM,ÌýFonÌýEA. Syntaxin-17 delivers PINK1/parkin-dependent mitochondrial vesicles to the endolysosomal system.ÌýJ. Cell Biol.Ìý2016; 214(3):275-91Ìý

Durcan TM,ÌýFonÌýEA. The three P’s of Mitophagy: PARKIN, PINK1 and Post-Translational Modifications.ÌýGenes Dev.Ìý2015; 29(10):989-999
Ìý
Koyano F, Okatsu K, Kosako H, Tamura Y, Go E, Kimura M, Kimura Y, Tsuchiya H, Yoshihara H, Hirokawa T, Endo T,ÌýFonÌýEA, Trempe JF, Saeki Y, Tanaka K, Matsuda N.ÌýUbiquitin is phosphorylated by PINK1 to activate parkin.ÌýNature.Ìý2014; 510(7503):162-6
Ìý
Durcan TM, Tang MY, Pérusse JR, Dashti EA, Aguileta MA, McLelland GL, Gros P, Shaler TA, Faubert D, Coulombe B,ÌýFonÌýEA. USP8 Regulates Mitophagy by Removing K6-linked Ubiquitin Conjugates from Parkin.ÌýEMBO J. 2014;Ìý33(21):2473-91
Ìý
Trempe J-F, Sauvé, V, Grenier K, Seirafi, M, Tang MY, Ménade M, Krett J, Wong K, Kozlov G, Nagar B,ÌýFonÌýEA, Gehring K. Structure of parkin reveals mechanism of ubiquitin ligase activation.ÌýScience. 2013; 340(6139):1451-5

Research areas: 
Neurodegenerative Disorders

The Neuro logoÌý91ºÚÁÏÍø logo

Ìý

The Neuro (Montreal Neurological Institute-Hospital)Ìýis a bilingual academic healthcare institution. We are aÌý91ºÚÁÏÍø research and teaching institute; delivering high-quality patient care, as part of the Neuroscience Mission of the 91ºÚÁÏÍø Health Centre.ÌýWe areÌýproud to be a Killam Institution, supported by the Killam Trusts.

Ìý

Ìý

Back to top